El-Menoufy, M. A. and Ahmed, M. A. revealed that repeated evaluation of WT1 transcript levels in CML patients might be a valuable marker for predicting early and abrupt disease progression [28]. This evidence concerns the gene WT1 and chronic myelogenous leukemia, BCR-ABL1 positive.